This illustration was developed to showcase two novel Kleo Pharmaceuticals technologies. Antibody Recruiting Molecules (ARM™s) are bispecific molecules which assist in the recruitment of endogenous antibodies to target diseased cells to initiate immune destruction. Monoclonal Antibody Therapy Enhancers (MATE™s) facilitate the chemical engineering of existing antibodies, which are then administered to clients to enhance the immune’s response to target cells.
Related Illustrations
